Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/02/039895
CTRI/2022/02/039895
Not yet recruiting
未知

COMPARISON OF SAFETY AND EFFICACY OF FLUTICASONE FUROATE/VILANTEROL VERSUS FLUTICASONE FUROATE/SALMETEROL IN THE TREATMENT OF MODERATE STABLE COPD PATIENTS - A RANDOMIZED CONTROLLED TRIA

SRM college of pharmacy0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: J40-J47- Chronic lower respiratory diseases

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: J40-J47- Chronic lower respiratory diseases
Sponsor
SRM college of pharmacy
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
SRM college of pharmacy

Eligibility Criteria

Inclusion Criteria

  • •subjects with clinical history of moderate copd in accordance with the following definition by the european respiratory society.
  • •subjects with measured FEV1/FVC ratio of 0\.70 at screening.
  • •subjects with measured FEVI 70% of predicted normal values.
  • •patient willing to participate in the study and providing informed consent.

Exclusion Criteria

  • •patients with \<30 and \>70 years of age and women of reproductive age (15\-45 years).
  • •patients with symptoms of acute exacerbation.
  • •patients with uncontrolled diabetes mellitus and hypertension.
  • •patients on immunosuppressive drugs.
  • •patients with known trigger factors of asthma and malignancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
Efficacy and safety of Fluticasone furoate with montelukast vs Fluticasone furoate with Cetirizine in patients with allergic rhinitisHealth Condition 1: J309- Allergic rhinitis, unspecified
CTRI/2023/10/059253SRM institute of science and technology
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPD
EUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
Active, not recruiting
Phase 1
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000